[HTML][HTML] OA04. 05 trastuzumab deruxtecan in HER2-overexpressing metastatic non-small cell lung cancer: interim results of DESTINY-Lung01
K Nakagawa, M Nagasaka, E Felip, J Pacheco… - Journal of Thoracic …, 2021 - jto.org
Methods Patients with HER2-overexpressing metastatic NSCLC were treated with T-DXd 6.4
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …
OA04. 05 Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
K Nakagawa, M Nagasaka, E Felip, J Pacheco… - Journal of Thoracic …, 2021 - Elsevier
Methods Patients with HER2-overexpressing metastatic NSCLC were treated with T-DXd 6.4
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …
mg/kg every 3 weeks. The primary endpoint was ORR (CR+ PR) by ICR. Additional …